New hives drug faces off against xolair in major trial
NCT ID NCT06365879
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug (omalizumab α) against the approved drug Xolair for people with chronic hives that don't get better with antihistamines. About 392 adults aged 15 to 75 will receive either the new drug or Xolair to see how well it reduces itching and hives over 12 weeks. The goal is to find out if the new drug works just as well and is safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC SPONTANEOUS URTICARIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huashan Hospital
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug aims to quiet chronic hives
- New pill for chronic hives enters first human tests
- New pill for chronic hives tested in everyday clinics
- New hope for chronic hive sufferers: phase 3 drug trial shows promise
- New drug HRS-3095 aims to soothe stubborn hives
- New shot could tame stubborn hives for good